Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Short term Debt (2019 - 2025)

Historic Short term Debt for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $105000.0.

  • Pulmonx's Short term Debt rose 606.06% to $105000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $105000.0, marking a year-over-year increase of 606.06%. This contributed to the annual value of $3.2 million for FY2024, which is 4737.82% up from last year.
  • Per Pulmonx's latest filing, its Short term Debt stood at $105000.0 for Q3 2025, which was up 606.06% from $104000.0 recorded in Q2 2025.
  • In the past 5 years, Pulmonx's Short term Debt registered a high of $7.8 million during Q1 2025, and its lowest value of $90000.0 during Q4 2022.
  • For the 5-year period, Pulmonx's Short term Debt averaged around $1.8 million, with its median value being $472000.0 (2021).
  • Its Short term Debt has fluctuated over the past 5 years, first plummeted by 9819.55% in 2023, then skyrocketed by 564835.16% in 2024.
  • Quarter analysis of 5 years shows Pulmonx's Short term Debt stood at $91000.0 in 2021, then fell by 1.1% to $90000.0 in 2022, then surged by 2294.44% to $2.2 million in 2023, then surged by 47.38% to $3.2 million in 2024, then tumbled by 96.69% to $105000.0 in 2025.
  • Its Short term Debt stands at $105000.0 for Q3 2025, versus $104000.0 for Q2 2025 and $7.8 million for Q1 2025.